共 50 条
- [1] The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma - First Results of a phase II Trial by the German DSMM GroupBLOOD, 2010, 116 (21) : 810 - 810Knop, StefanLanger, ChristianEngelhardt, MonikaMuegge, LarsReichle, AlbrechtRoellig, ChristophGramatzki, MartinRoesler, WolfTopp, Max S.Wesemeier, CarmenHertenstein, BerndSturm, IsridDechow, TobiasKortuem, MartinSauerwein, MarianneEinsele, HermannBargou, Ralf
- [2] Lenalidomide, Adriamycin and Dexamethasone (RAD) As An Induction Regimen In Newly Diagnosed Multiple Myeloma-Interim Results From a German Multicenter Phase II TrialBLOOD, 2013, 122 (21)Knop, StefanLanger, ChristianEngelhardt, MonikaMuegge, Lars O.Roesler, WolfReichle, AlbrechtRoellig, ChristophHertenstein, BerndGramatzki, MartinBassermann, FlorianOstermann, HelmutSturm, IsridRinghoffer, MarkSchaefer-Eckart, KerstinKraus, SabrinaEinsele, HermannBargou, Ralf C.
- [3] RESULTS OF A PHASE I/II TRIAL OF DEUTSCHE STUDIENGRUPPE MULTIPLES MYELOM, SHOWING EFFICACY AND SAFETY OF RAD REGIMEN (REVLIMID®, ADRIAMYCIN®, DEXAMETHASONE) IN RELAPSED/REFRACTORY MULTIPLE MYELOMAHAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 256 - 256Knop, S.Gerecke, C.Liebisch, P.Topp, M. S.Platzbecker, U.Vollmuth, C.Einsele, H.Bargou, R.
- [4] The efficacy and toxicity of the RAD regimen (Revlimid®, Adriamycin® Dexamethasone) in relapsed and refractory multiple myeloma -: A phase I/II trial of "Deutsche Studiengruppe Multiples Myelom"BLOOD, 2007, 110 (11) : 797A - 797AKnop, StefanGerecke, ChristianLiebisch, PeterTopp, Max S.Hess, GeorgPlatzbecker, UweFrohnert, SandraEinsele, HermannBargou, Ralf
- [5] Combination of Bendamustine, Lenalidomide, and Dexamethasone In Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of a Phase I Clinical TrialBLOOD, 2010, 116 (21) : 435 - 435Lentzsch, SuzanneO'Sullivan, AmyKennedy, RyanGill, NavkiranjitAndreas, CarrieGardner, DianeLalo, SilvanaBurt, SteveRedner, Robert L.Volkin, RobertRoodman, DavidMapara, Markus Y.Viverette, FrankAgha, MounzerZonder, Jeffrey A.
- [6] Lenalidomide, Adriamycin and Dexamethason (RAD) in Relapsed and Refractory Multiple Myeloma: Final Results from a Phase I/II Trial of "Deutsche Studiengruppe Multiples Myelom".BLOOD, 2008, 112 (11) : 961 - 961Gerecke, ChristianKnop, StefanTopp, Max S.Liebisch, PeterVollmuth, ChristinaPlatzbecker, UweMaeder, UweEinsele, HermannBargou, Ralf C.
- [7] A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myelomaAMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (12) : E319 - E322Lee, Hans C.Shah, Jatin J.Feng, LeiMorphey, AshleyJohnson, Ralph J.Wesson, Emily T.Wang, Michael L.Alexanian, RaymondThomas, Sheeba K.Orlowski, Robert Z.Weber, Donna M.
- [8] Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial resultsHEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 695 - 703Ailawadhi, SikanderParrondo, Ricardo D.Moustafa, Muhamad AlhajLaPlant, Betsy R.Alegria, VictoriaChapin, DustinRoy, VivekSher, TaimurPaulus, AneelChanan-Khan, Asher A.
- [9] Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple MyelomaBLOOD, 2009, 114 (22) : 744 - 744Reece, Donna E.Masih-Khan, EstherKhan, AroojDean, SaimaAnglin, PeterChen, ChristineKukreti, VishalMikhael, Joseph R.Trudel, Suzanne
- [10] Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple MyelomaBLOOD, 2010, 116 (21) : 1260 - 1260Reece, Donna E.Masih-Khan, EstherKhan, AroojDean, SaimaFung, SharonAnglin, PeterChen, ChristineKukreti, VishalMikhael, Joseph R.Trudel, Suzanne